Poland· PL-100404728
Juluca
A dolutegravir and rilpivirine product containing dolutegravirum + rilpivirini hydrochloridum, registered in Poland by ViiV Healthcare BV. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Dolutegravir and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR21 (dolutegravir and rilpivirine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Dolutegravir and rilpivirine · ATC J05AR21
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Dolutegravirum + Rilpivirini hydrochloridum
- Manufacturer
- ViiV Healthcare BV
- Country
- Poland (PL)
- ATC code
- J05AR21
- ATC class
- Dolutegravir and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991370107
- gtin05909991370114
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dolutegravir and rilpivirine in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJULUCAViiV Healthcare BV, Amersfoort
- United StatesJulucaViiV Healthcare Company
- FinlandJulucaAbacus Medicine A/S
- FranceJULUCA 50 mg/25 mg, comprimé pelliculéVIIV HEALTHCARE (PAYS-BAS)
- CanadaJULUCAVIIV HEALTHCARE ULC
- IcelandJulucaViiV Healthcare BV
- NetherlandsJuluca 50 mg/25 mg, filmomhulde tablettenViiV healthcare B.V.
- NorwayJulucaViiV Healthcare BV (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Juluca
- Liechtenstein · Juluca
- Norway · Juluca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df775e5b-e43a-4239-aba7-70072e2812d2 GET /v1/drugs/df775e5b-e43a-4239-aba7-70072e2812d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg + 25 mg",
"packaging": "05909991370107 ¦ Rpz ¦ EU/1/18/1282/001 ¦ 127825\n30 tabl.\n05909991370114 ¦ Rpz ¦ EU/1/18/1282/002 ¦ 127826\n90 tabl.",
"substance": "Dolutegravirum 50 mg + Rilpivirini hydrochloridum 25 mg",
"common_name": "Dolutegravirum + Rilpivirini hydrochloridum",
"pl_product_id": "100404728",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about dolutegravir and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.